Investing.com -- The lawsuit filed by the U.S. Federal Trade Commission (FTC) against pharmacy benefit managers (PBMs) over insulin pricing practices is set to resume. The case had been temporarily halted following President Donald Trump’s dismissal of two Democratic commissioners from the agency.

Earlier this week, the FTC had put the case on hold due to the recusal of Chairman Andrew Ferguson and fellow Republican Melissa Holyoak. Both had decided to step back from the case due to their past involvement with PBM-related cases.

On Thursday, Ferguson stated that after consulting with FTC ethics officials, he decided to reverse his recusal. This move allows the case against UnitedHealth Group Inc (NYSE: UNH )’s Optum unit, CVS Health Corp (NYSE: CVS )’s CVS Caremark, and Cigna Corp (NYSE: CI )’s Express Scripts to proceed.

Before becoming FTC Chairman, Ferguson held the position of Virginia’s solicitor general and had advised the state’s attorney general on a class action against PBMs. He is expected to request the FTC’s in-house court to restart the case.

The defendants, Optum, Caremark, and Express Scripts, have not yet responded to requests for comment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.